| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
15-Hydroxypentadecanoic acid is a synthetic intermediate and fatty acid derivative rather than a direct pharmacological agent. As a building block, it does not have specific biological receptors as its primary targets. The compound's hydroxyl and carboxylic acid groups allow for various chemical transformations, including esterification, lactonization, and oxidation. It is used in the synthesis of macrocyclic lactone musk compounds. Its primary applications are as a synthetic intermediate for fragrance compounds and as a biochemical reagent for fatty acid research.
|
|---|---|
| ln Vitro |
15- Hydroxypentadecanoic acid is a biochemical reagent that can be utilized in research pertaining to life sciences as an organic compound or biological material.
In vitro, 15-hydroxypentadecanoic acid is used as a biochemical reagent and organic compound for biomedical research. It is used in the synthesis of the macrocyclic lactone musk compounds exaltolide and phoracantholide I. Cellular assays are not typically performed with this compound as a direct cell-modulating agent, as its primary applications are in fragrance chemistry and organic synthesis. The compound's fatty acid structure makes it valuable for studying lipid metabolism and fatty acid chemistry. |
| ln Vivo |
In vivo data for 15-hydroxypentadecanoic acid is limited, as it is primarily a research reagent and synthetic intermediate. The compound is classified for research use only and is not intended for human or veterinary therapeutic applications. Its primary applications are in the synthesis of fragrance compounds and as a research chemical. Specific in vivo data for the parent compound is not available in the public literature. The compound is not a therapeutic candidate.
|
| Enzyme Assay |
In vitro assays for 15-hydroxypentadecanoic acid typically evaluate its use as a synthetic intermediate. A standard protocol involves using the compound in chemical reactions to prepare macrocyclic lactones. The compound is dissolved in organic solvents such as dichloromethane or THF. Cyclization reactions are performed using appropriate reagents and catalysts. The resulting lactones are characterized by NMR, MS, and other analytical techniques. The compound's purity and functional group integrity are critical for successful synthesis.
|
| Cell Assay |
Cellular assays for 15-hydroxypentadecanoic acid are not standard, as the compound is primarily used as a synthetic intermediate for fragrance compounds rather than as a cell-modulating agent. The compound's fatty acid structure suggests potential for incorporation into lipid metabolism. Any cellular studies would focus on evaluating its effects on lipid metabolism or cytotoxicity. A typical protocol would involve culturing appropriate cell lines in growth medium at 37°C with 5% CO₂. Cells would be treated with varying concentrations of the compound. Cell viability and lipid metabolism markers would be assessed.
|
| Animal Protocol |
In vivo animal studies for 15-hydroxypentadecanoic acid are not standard, as it is primarily a research reagent and synthetic intermediate. The compound is classified for research use only and is not intended for human or veterinary applications. Any animal studies would be limited to toxicological evaluations of the compound as an industrial chemical or fragrance ingredient. The compound's primary value lies in its use as a synthetic intermediate for fragrance compounds. Specific in vivo protocols are not available in the public literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 15-hydroxypentadecanoic acid is limited, as it is primarily a research reagent. The compound has a molecular weight of 258.40 g/mol and a molecular formula of C₁₅H₃₀O₃. It is a solid at room temperature with a melting point of 85-89°C. It is soluble in chloroform, ethanol, methanol, and DMSO. It is stored at 2-8°C. As a hydroxy fatty acid, it may undergo beta-oxidation and conjugation. Specific ADME data is not available.
|
| Toxicity/Toxicokinetics |
15-Hydroxypentadecanoic acid is classified for research use only and is not intended for human or veterinary applications. Standard safety precautions include handling with appropriate personal protective equipment (gloves, lab coat, safety goggles) in a well-ventilated area. The compound should be stored at 2-8°C away from incompatible materials. Acute toxicity data is not readily available in the public literature. As with all research chemicals, appropriate laboratory safety practices should be followed. No specific LD₅₀ values are available in the public domain.
|
| Additional Infomation |
15-Hydroxypentadecanoic acid (15-Hydroxypentadecanoic acid) is an ω-hydroxy long-chain fatty acid, formed by replacing a hydrogen atom on the terminal methyl group of pentadecanoic acid with a hydroxyl group. It is a straight-chain saturated fatty acid and also an ω-hydroxy long-chain fatty acid. Functionally, it is related to pentadecanoic acid. It is the conjugate acid of 15-hydroxypentadecanoate. 15-Hydroxypentadecanoic acid has been reported in both Arabidopsis thaliana and Angelica sinensis, and relevant data are available for reference.
15-Hydroxypentadecanoic acid (15-Hydroxy C15:0 fatty acid, CAS 4617-33-8) is a biochemical reagent with the molecular formula C₁₅H₃₀O₃. It is an omega-hydroxy-long-chain fatty acid used in the synthesis of the macrocyclic lactone musk compounds exaltolide and phoracantholide I. The compound is classified as a research-use-only compound not intended for diagnostic or therapeutic purposes. |
| Molecular Formula |
C15H30O3
|
|---|---|
| Molecular Weight |
258.40
|
| Exact Mass |
258.219
|
| CAS # |
4617-33-8
|
| PubChem CID |
78360
|
| Appearance |
White to light yellow solid powder
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
400.9±18.0 °C at 760 mmHg
|
| Melting Point |
85-89 °C(lit.)
|
| Flash Point |
210.4±17.7 °C
|
| Vapour Pressure |
0.0±2.1 mmHg at 25°C
|
| Index of Refraction |
1.468
|
| LogP |
4.62
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
18
|
| Complexity |
181
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(CCCCCCCO)CCCCCCC(=O)O
|
| InChi Key |
BZUNJUAMQZRJIP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H30O3/c16-14-12-10-8-6-4-2-1-3-5-7-9-11-13-15(17)18/h16H,1-14H2,(H,17,18)
|
| Chemical Name |
15-hydroxypentadecanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.8700 mL | 19.3498 mL | 38.6997 mL | |
| 5 mM | 0.7740 mL | 3.8700 mL | 7.7399 mL | |
| 10 mM | 0.3870 mL | 1.9350 mL | 3.8700 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
